Sanofi (SNYNF) on Wednesday said that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, the company's drug candidtae for the treatment of multiple myeloma.
SAR446523 is currently being evaluated in a Phase 1 study.
Orphan drug designation provides benefits including market exclusivity for 7 years after approval of the drug, tax credits, and exemption from certain fees.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.